Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company developing therapeutic technologies through collaborations with medical-device companies. Its flagship candidates are AVIM Therapy, a bioelectronic treatment for uncontrolled hypertension designed for integration into cardiac pacemakers,… From the company’s description.
Over the twelve months to Jun 30, 2026, Orchestra BioMed Holdings, Inc. reported revenue of $31.98M, up 986.1% from a year earlier, and a net loss of $59.03M. Its operating margin was −181.4%, and operations used $58.32M in cash. In fiscal 2025, it reported revenue of $33.48M, up 1169.2% from fiscal 2024, and a net loss of $52.70M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Orchestra BioMed Holdings, Inc. does
In the company’s own words
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company developing therapeutic technologies through collaborations with medical-device companies. Its flagship candidates are AVIM Therapy, a bioelectronic treatment for uncontrolled hypertension designed for integration into cardiac pacemakers, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), a drug-device candidate that delivers sirolimus to artery walls during balloon angioplasty. Both are in pivotal-stage clinical development; neither has established safety and efficacy with regulatory approval. Orchestra is conducting the BACKBEAT study of AVIM Therapy with Medtronic, which holds exclusive global commercialization rights for the pacemaker-indicated population if the therapy is approved. The company is also conducting a U.S. pivotal trial of Virtue SAB for coronary in-stent restenosis and has granted Terumo a right of first refusal concerning rights or distribution for coronary artery disease. Its pipeline also includes cardiac neuromodulation therapy for heart failure and potential applications of its sirolimus formulation in other indications. Orchestra was formed in 2018 through the combination of businesses developing Virtue SAB and AVIM Therapy.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- NEW HOPE, PA
- Fiscal year end
- December
- CIK
- 1814114
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Orchestra BioMed Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Orchestra BioMed Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Orchestra BioMed Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Orchestra BioMed Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Orchestra BioMed Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”